These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11797701)

  • 1. Kickbacks, courtesies or cost-effectiveness?: Application of the Medicare antikickback Law to the marketing and promotional practices of drug and medical device manufacturers.
    Bulleit TN; Krause JH
    Food Drug Law J; 1999; 54(3):279-323. PubMed ID: 11797701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
    Reiss JB
    Food Drug Law J; 1997; 52(1):99-108. PubMed ID: 10346713
    [No Abstract]   [Full Text] [Related]  

  • 3. Percentage compensation arrangements: suspect, but not illegal.
    Fedor FP
    Healthc Financ Manage; 2001 Jan; 55(1):48-52. PubMed ID: 11211487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
    Simmer WS
    Manag Care Interface; 2002 Jan; 15(1):90-2. PubMed ID: 11828611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fraud and abuse. Setting the limits on physicians' entrepreneurship.
    Hyman DA; Williamson JV
    N Engl J Med; 1989 May; 320(19):1275-8. PubMed ID: 2651929
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug marketing from an Office of Inspector General enforcement perspective.
    Foley LA
    Food Drug Law J; 1995; 50(2):309-12. PubMed ID: 10342999
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent multistate enforcement initiatives: prescription drug promotional practices.
    Woodward D
    Food Drug Law J; 1995; 50(2):295-300. PubMed ID: 10342997
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicare and Medicaid programs; fraud and abuse OIG anti-kickback provisions--HHS. Proposed rule.
    Fed Regist; 1989 Jan; 54(13):3088-95. PubMed ID: 10304257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SmithKline settles charges of kickbacks at 3 labs.
    Burda D
    Mod Healthc; 1989 Dec; 19(52):3. PubMed ID: 10304218
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
    Reichertz PS
    Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
    [No Abstract]   [Full Text] [Related]  

  • 11. Medicare and state health care programs: fraud and abuse; ambulance replenishing safe harbor under the anti-kickback statute. Final rule.
    Office of Inspector General (OIG), HHS
    Fed Regist; 2001 Dec; 66(233):62979-91. PubMed ID: 11778625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OIG advises that marketing/distribution arrangement may violate anti-kickback provision.
    Ramsey RB
    Benders Health Care Law Mon; 1998 May; ():19-22. PubMed ID: 10181979
    [No Abstract]   [Full Text] [Related]  

  • 13. Mirror, mirror on the wall--evaluating Fair Market Value for manufacturer-physician consulting arrangements.
    Eaton F; Reid J
    Food Drug Law J; 2010; 65(1):141-57, iii. PubMed ID: 24475537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experts review effects of ruling on kickbacks.
    Burda D
    Mod Healthc; 1991 Jul; 21(29):46. PubMed ID: 10111854
    [No Abstract]   [Full Text] [Related]  

  • 15. Curing the health care industry: government response to Medicare fraud and abuse.
    Hearn FJ
    J Contemp Health Law Policy; 1989; 5():175-201. PubMed ID: 10303502
    [No Abstract]   [Full Text] [Related]  

  • 16. Achieving compliance with medical call centers.
    Darling WD; Wood KM
    Healthc Financ Manage; 2002 Sep; 56(9):82-6. PubMed ID: 12235980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A call for balancing of agency sentinel priorities.
    Eiland GW
    J Health Law; 1999; 32(4):503-14. PubMed ID: 10662437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare and state health care programs; fraud and abuse: OIG civil money penalties under the Medicare prescription drug discount card program. Final rule.
    Office of Inspector General (OIG), HHS
    Fed Regist; 2004 Dec; 69(239):74451-3. PubMed ID: 15597491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antikickback versus stark: what's the difference?
    Watnik RL
    Healthc Financ Manage; 2000 Mar; 54(3):66-7. PubMed ID: 10847919
    [No Abstract]   [Full Text] [Related]  

  • 20. "Sentinel effect" shows fraud control effort works.
    Thornton DM
    J Health Law; 1999; 32(4):493-502. PubMed ID: 10662436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.